Cue Biopharma, Inc. Debt Securities, Available-for-sale, Amortized Cost
Cue Biopharma, Inc. (CUE) had Debt Securities, Available-for-sale, Amortized Cost of $6.97 million as of 2025-09-30, per its 10-Q filed 2025-11-12.
Financial Statements › Notes
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2025-11-12
- 2025-09-30: Debt Securities, Available-for-sale, Amortized Cost $6.97M.
- 2023-06-30: Debt Securities, Available-for-sale, Amortized Cost $4.99M.
- 2023-03-31: Debt Securities, Available-for-sale, Amortized Cost $9.92M.
- 2022-12-31: Debt Securities, Available-for-sale, Amortized Cost $24.77M; Debt Securities, Available-for-sale, Amortized Cost as first filed $24.77M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost | Debt Securities, Available-for-sale, Amortized Cost as first filed |
|---|---|---|
| 2025-09-30 | $6.97M 10-Q · filed 2025-11-12 | |
| 2023-06-30 | $4.99M 10-Q · filed 2023-08-08 | |
| 2023-03-31 | $9.92M 10-Q · filed 2023-05-09 | |
| 2022-12-31 | $24.77M 10-K · filed 2024-03-28 | $24.77M 10-K · filed 2023-03-21 |
| 2022-09-30 | $29.55M 10-Q · filed 2022-11-14 | |
| 2022-03-31 | $0.00 10-Q · filed 2023-05-09 | |
| 2021-12-31 | $0.00 10-K · filed 2023-03-21 | |
| 2020-12-31 | $10.00M 10-K · filed 2022-03-16 | |
| 2020-09-30 | $20.00M 10-Q · filed 2020-11-09 | |
| 2020-06-30 | $25.02M 10-Q · filed 2020-08-07 | |
| 2020-03-31 | $25.05M 10-Q · filed 2020-05-07 | |
| 2019-12-31 | $15.13M 10-K · filed 2021-03-09 | |
| 2019-06-30 | $4.00M 10-Q · filed 2019-08-08 | |
| 2019-03-31 | $8.97M 10-Q · filed 2019-05-08 | |
| 2018-12-31 | $18.42M 10-K · filed 2020-03-12 | |
| 2018-09-30 | $23.36M 10-Q · filed 2018-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |